Sign in Subscribe
BioMed

🧬 BioMed Pulse · 2026-06-24 02:01 UTC

BIOMED PULSE

Tuesday, June 24, 2026 — Daily Edition

⚡ TL;DR

The Bundibugyo Ebola outbreak in the DRC and Uganda has surged to 896 confirmed cases and 232 deaths as of June 17, making it the dominant global health emergency right now. The overall mood is urgent on the outbreak front, with cautious progress on food safety and longevity research.

🦠 OUTBREAKS & VIRUSES

EBOLA BUNDIBUGYO VIRUS — DRC AND UGANDA (ACTIVE PHEIC)

  • As of June 17, 2026, the DRC alone has recorded 896 confirmed cases and 232 confirmed deaths from Bundibugyo virus disease (BVD), with cross-border transmission continuing in Uganda. [1]
  • WHO declared this outbreak a Public Health Emergency of International Concern on May 17, 2026, determining it does not yet meet the threshold for pandemic emergency status. [2]
  • The IHR Emergency Committee issued temporary recommendations on May 22, advising enhanced surveillance, contact tracing, and port-of-entry screening globally. [3]
  • Africa CDC and WHO launched a joint continental Ebola response plan on June 5, targeting a fundraising goal of US$518 million to support African countries at risk. [4]
  • WHO released its first comprehensive clinical management guidelines for all filovirus diseases, including Ebola and Marburg, on June 17 — timed directly to the BVD outbreak response. [5]
  • WHO convened expert advisory groups on May 28 to assess candidate vaccines and therapeutics specifically for Bundibugyo virus, a strain for which no approved countermeasures exist. [6]
  • CDC mobilized an international response starting May 17 and expanded enhanced airport Ebola screening from Washington-Dulles International Airport to Atlanta Hartsfield by May 23. [7] [8]
  • CDC World Cup 2026 activation is running concurrently with Ebola response, given large international gatherings across US host cities. [9]

HANTAVIRUS — ANDES STRAIN, M/V HONDIUS CRUISE SHIP (MULTI-COUNTRY)

  • A cluster of Andes hantavirus cases linked to passengers aboard the M/V Hondius cruise ship was first reported to WHO on May 2, 2026; the fourth WHO Disease Outbreak News update as of May 28 confirmed continued case investigation across multiple countries. [10]
  • As of the May 13 update, two additional confirmed cases were reported beyond the original seven identified, spanning passengers from 23 countries.
  • WHO Director-General Tedros addressed a personal letter to the people of Tenerife on May 9, commending local cooperation in safely disembarking and caring for the affected passengers.
  • CDC provided multiple daily briefings in mid-May and confirmed on May 8 that the risk to the general American public remained extremely low.

MPOX — CLADE IB AND RECOMBINANT STRAIN (GLOBAL)

  • A WHO Disease Outbreak News report from December 2025 documented local clade Ib MPXV transmission among men who have sex with men in previously unaffected countries.
  • As of February 14, 2026, WHO reported two cases of a recombinant mpox strain containing genomic elements of both clade Ib and clade IIb — a known natural process when two strains infect the same individual simultaneously.

NIPAH VIRUS — INDIA AND BANGLADESH

  • India reported two laboratory-confirmed Nipah virus cases in healthcare workers at a private hospital in Barasat, North 24 Parganas district, West Bengal, on January 26, 2026.
  • Bangladesh reported one confirmed Nipah case in Rajshahi Division on February 3, 2026; the patient developed fever and neurological symptoms on January 21, 2026.

MEASLES — BANGLADESH (ONGOING)

  • As of April 4, 2026, Bangladesh reported 19,161 suspected measles cases and 2,897 laboratory-confirmed cases, affecting 58 of 64 districts across all eight divisions.

FOOD SAFETY OUTBREAKS — ACTIVE US ALERTS

  • CDC warns of an active Listeria outbreak linked to chicken fettuccine alfredo meals, with 17 people sickened from the same strain as of June 19, 2026.
  • CDC issued a Listeria outbreak alert tied to requesón/soft ricotta cheese as of June 5, 2026.
  • A Salmonella outbreak linked to pistachio cream has sickened four people as of June 16, 2026.
  • A Salmonella outbreak linked to backyard poultry has expanded to sicken 150 additional people, with over one quarter of cases in children under five years old.

ANTIMICROBIAL RESISTANCE

  • A September 2025 CDC report found a dramatic increase in dangerous drug-resistant bacteria in the US, flagging the trend as a growing acute threat.
  • An extensively drug-resistant Salmonella outbreak linked to moringa powder capsules resulted in three hospitalizations as of February 2026, with growing numbers of linked illnesses and outbreaks tracked through May 2026.

🧬 LONGEVITY & AGING

CELLULAR SENESCENCE AND KIDNEY REPAIR

  • A June 2026 Europe PMC study found that the enzyme AMD1, which controls polyamine metabolism, governs whether tubular cells in the kidney repair themselves or fall into permanent senescence after injury — pointing to a potential therapeutic target for preventing age-related kidney decline.
  • Cartilage cell research published June 13, 2026 identified a conserved nine-gene module that drives dedifferentiation in auricular chondrocytes independently of senescence, revealing a new mechanism of tissue aging in cartilage.

DNA METHYLATION, TELOMERE LENGTH, AND VASCULAR AGING

  • A Europe PMC genetic study from May 2026 used Mendelian randomization to link DNA methylation-estimated phenotypes and shorter telomere length to increased risk of intracranial aneurysms, suggesting biological aging clocks track cardiovascular risk beyond traditional markers.

FRAILTY AND HYPERTENSION IN OLDER ADULTS

  • A June 2026 longitudinal study from India found significant associations between hypertension and frailty in middle-aged and older adults, using data from the Longitudinal Ageing Study in India — reinforcing that controlling blood pressure may slow the frailty trajectory.

HANDGRIP STRENGTH AS A LONGEVITY BIOMARKER

  • A June 2026 Europe PMC prospective study using Chinese and European cohorts found that combined handgrip strength inversely predicts incident chronic digestive diseases in older adults, adding to evidence that muscular fitness is a reliable longevity marker.

COLLAGEN OXIDATION AND TISSUE AGING

  • Research published June 11, 2026 examined how both enzymatic and non-enzymatic oxidation degrades fibrillar collagen, the main structural protein in skin, bone, and tendons — a key mechanism of age-related tissue stiffening and loss of resilience.

MATERNAL DIET AND NEONATAL MICROBIOME

  • A June 2026 Gut Microbes study by Kadyan et al. showed that maternal diet shapes neonatal microbiome development and neurometabolic resilience, suggesting longevity programming may begin before birth through gut colonization patterns.

URIC ACID AND NEUROPROTECTION VIA FERROPTOSIS

  • A June 2026 Redox Reports study found uric acid reduces neuroinflammation in LPS-induced BV2 cells and in a mouse Parkinson's disease model by inhibiting ferroptosis through the Nrf2 signaling pathway, a finding relevant to age-related neurodegeneration.

REPRODUCTIVE AGING AND DELAYED CHILDBEARING

  • A June 2026 narrative review in the Journal of Obstetrics and Gynaecology examined the biology of ovarian reserve decline, oocyte quality deterioration, and uterine aging, noting increasing clinical relevance as mean maternal age at first birth rises globally.

💊 NEW CURES & APPROVALS

NOTE ON TODAY'S DRUG DATA

  • The openFDA items in today's data window consist entirely of supplemental approvals (SUPPL AP) for existing opioid analgesics (morphine sulfate, meperidine, oxycodone, oxymorphone, methadone, hydrocodone, codeine) by manufacturers including Teva, Epic Pharma, Actavis Elizabeth, Hikma, ANI Pharmaceuticals, Lannett, and Aurolife Pharma — these represent manufacturing or labeling updates, not new drug approvals.
  • One supplemental approval was recorded for RINVOQ LQ (upadacitinib liquid formulation) from AbbVie, which is already approved for inflammatory conditions including rheumatoid arthritis, atopic dermatitis, and Crohn's disease; the SUPPL AP notation indicates a supplemental change rather than a new indication.

🧪 CLINICAL TRIALS

ALZHEIMER'S DISEASE — MK-2214 (MERCK)

  • A new ClinicalTrials.gov entry (NCT07033494) posted June 23, 2026, is studying MK-2214 in people with early Alzheimer's disease, aiming to determine whether the investigational agent slows brain changes associated with the disease.

RELAPSED/REFRACTORY MULTIPLE MYELOMA — MIRDAMETINIB PLUS SIROLIMUS

  • NCT06876142, posted June 23, 2026, is evaluating the combination of mirdametinib (a MEK inhibitor) and sirolimus (an mTOR inhibitor) for patients with RAS-mutated relapsed/refractory multiple myeloma — targeting two nodes of the same proliferation pathway simultaneously.

INTRATHECAL GENE THERAPY — SLC13A5 CITRATE TRANSPORTER DISORDER

  • NCT07102524, a Phase 1/2 open-label study posted June 23, 2026, is evaluating a single lumbar intrathecal dose of TSHA-105 in individuals with SLC13A5 Citrate Transporter Disorder, a rare pediatric neurological condition caused by defective citrate transport across the blood-brain barrier.

NEUROENDOCRINE CANCER — BI 764532 PLUS CHEMOTHERAPY (BOEHRINGER INGELHEIM, DAREON-7)

  • NCT06132113 (DAREON-7) is testing BI 764532, a DLL3-targeting agent, in combination with chemotherapy for adults with advanced DLL3-positive neuroendocrine carcinoma; trial updated June 23, 2026.

HER2-ALTERED CANCERS — ZONGERTINIB (BEAMION PANTUMOR-1)

  • NCT06581432 evaluates zongertinib, an oral HER2-selective tyrosine kinase inhibitor, across multiple advanced solid tumor types with HER2 alterations in adults 18 and older; updated June 23, 2026.

FRAILTY AND PHYSICAL DECONDITIONING — SHAPE PROJECT

  • NCT07663955, updated June 23, 2026, is investigating a hospital-based adapted physical activity program (SHAPE) to prevent frailty and physical deconditioning in older patients hospitalized for decompensated chronic respiratory diseases.

OBESITY — ALPHA-LIPOIC ACID PLUS MIRABEGRON

  • NCT05713799 is evaluating the combination of alpha-lipoic acid (a dietary supplement) and mirabegron (a beta-3 adrenergic agonist) as a potential metabolic treatment for obesity in both men and women; updated June 23, 2026.

IMMUNE AGING IN TRISOMY 21 — NATURAL HISTORY STUDY

  • NCT07416201, posted June 23, 2026, is studying immune system dysregulation and aging in people with Down syndrome (Trisomy 21), including the long-term effect of thymectomy performed during congenital heart surgery on immune aging trajectories.

📢 PUBLIC HEALTH

ACIP MEETING — JUNE 25-26, 2025 OUTCOMES

  • CDC's Advisory Committee on Immunization Practices concluded its June 25-26, 2025 meeting with a joint statement; the agenda covered multiple vaccine discussions including individual-based decision-making frameworks.

NEW WORLD SCREWWORM — CDC EMERGENCY OPERATIONS CENTER ACTIVATED

  • CDC activated its Emergency Operations Center on June 12, 2026 to respond to New World Screwworm (Cochliomyia hominivorax), a parasitic fly whose larvae can infest living tissue in mammals and humans, marking a significant public health escalation.

INFANT BOTULISM — NARA ORGANICS FORMULA

  • CDC issued an outbreak update on June 13, 2026 urging parents to immediately stop using all Nara Organics Whole Milk Organic Infant Formula, which has been linked to confirmed infant botulism cases.

WHO GLOBAL HEALTH STATISTICS 2026

  • WHO's World Health Statistics 2026 report, published May 13, 2026, warned that global health gains are facing reversal, with progress on major targets described as uneven, slowing, and in some areas going backward.

WHO PANDEMIC AGREEMENT — PATHOGEN ACCESS AND BENEFIT SHARING

  • On June 15, 2026, WHO Director-General Tedros and Brazilian partners issued an open letter to G7, G20, and BRICS leaders urging finalization of the Pathogen Access and Benefit Sharing (PABS) annex of the WHO Pandemic Agreement, calling it unfinished essential business.

FOOD SAFETY — GLOBAL BURDEN

  • WHO released new estimates on June 4, 2026 showing unsafe food causes 866 million illnesses and 1.5 million deaths annually worldwide, with children under five facing nearly three times the illness risk of older populations.

CDC TRAVELER-BASED GENOMIC SURVEILLANCE

  • CDC announced on January 30, 2026 that its voluntary air travel biosurveillance program surpassed one million participants, expanding the agency's capacity to detect novel pathogens at ports of entry.

This briefing is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider for personal health decisions.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus, Democratic Republic of the Congo & Uganda — WHO Disease Outbreak News
  2. Epidemic of Ebola Disease caused by Bundibugyo virus in the Democratic Republic of the Congo and Uganda determined a pub — WHO News
  3. First meeting of the IHR Emergency Committee regarding the epidemic of Ebola Bundibugyo virus disease in the Democratic — WHO News
  4. Africa CDC and WHO launch joint continental Ebola response plan — WHO News
  5. WHO issues comprehensive guidelines on filovirus disease, including Ebola and Marburg disease — WHO News
  6. Experts convened by WHO advise on candidate treatments and vaccines for Ebola disease caused by Bundibugyo virus — WHO News
  7. Enhanced Ebola Airport Screening Begins at Washington-Dulles International Airport — CDC Newsroom
  8. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
  9. Transcript - Update on Ebola Outbreak in the Democratic Republic of the Congo and Uganda and CDC's World Cup 2026(TM) ac — CDC Newsroom
  10. Hantavirus outbreak linked to cruise ship travel, Multi-locations — WHO Disease Outbreak News

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260624-02-v10 · 2026-06-24 02:01 UTC

Read next